Atorvastatin and cardiovascular risk in the elderly - Patient considerations

Clinical Interventions in Aging

Volumn 3, Issue 2, 2008, Pages 299-314

  Acharjee, Subroto ^a   Welty, Francine K ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Atorvastatin; Conary heart disease; Elderly patients; HMG CoA reductase inhibitors; Statins

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CARDIOVASCULAR AGENT; CHOLESTEROL; GEMFIBROZIL; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; SIMVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; AGED; ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COGNITION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; ELECTROCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; GERIATRICS; HEART ARREST; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIVER FUNCTION TEST; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; MUSCLE DISEASE; MYALGIA; NEOPLASM; PATIENT COMPLIANCE; PLEIOTROPY; PRACTICE GUIDELINE; PRIMARY PREVENTION; QUALITY OF LIFE; RESUSCITATION; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; AGED; CORONARY DISEASE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 47849131034     PISSN: 11769092     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Alsheikh-Ali AA, Maddukuri PV, Han H, et al. 2007. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol, 50:409-18.
2. Assmann G, Cullen P, Schulte H. 1998. The Miinster Heart Study (PROCAM). Results offollow-up at eight years. Eur Heart J, 19:A2-A11.
3. Avezum A, Makdisse M, Spencer F, et al. 2005. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J, 149:67-73.
4. Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists Collaborators. 2005. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants. Lancet, 366:1267-78.
5. Bandyopadhyay S, Bayer AJ, O'Mahony MS. 2001. Age and gender bias in statin trials. QJM, 94:127-32.
6. Benfante R, Reed D. 1990. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA, 263:393-96.
7. Benner JS, Glynn RJ, Mogun H, et al. 2002. Long-term persistence in use of statin therapy in elderly patients. JAMA, 288:455-61.
8. Benner JS, Pollack MF, Smith TW, et al. 2005. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm, 62:1468-75.
9. Bonow RO, Smaha LA, Smith SC Jr, et al. 2002. World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation, 106:1602-5.
10. Brown MS, Goldstein JL. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science, 232:34-47.
11. Cannon CP, Braunwald E, McCabe CH, et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators (PROVE IT-TIMI 22). 2004. Intensive versus moderate lipid lowering with statins after acute coronarysyndromes. N Engl J Med, 350:1495-504.
12. Castelli WP, Wilson PW, Levy D, et al. 1989. Cardiovascular risk factors in the elderly. Am J Cardiol, 63:12H-19H.
13. Colhoun HM, Betteridge DJ, Durrington PN, et al. 2004. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 364:685-96.
14. Conde K, Vergara-Jimenez M, Krause BR, et al. 1996. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J Lipid Res, 37:2372-82.
15. Cournot M, Cambou JP, Quentzel S, et al. 2006. Key factors associated with the under-prescription of statins in elderly coronary heart disease patients: results from the ELIAGE and ELICOUR surveys. Int J Cardiol, 111:12-18.
16. Cusack BJ. 2004. Pharmacokinetics in older persons. Am J Geriatr Pharmacother, 2:274-302.
17. Dale KM, Coleman CI, Henyan NN, et al. 2006. Statins and cancer risk: a meta-analysis. JAMA, 295:74-80.
18. Deedwania P, Stone PH, Bairey Metz CN, et al. 2007. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation, 115:700-7.
19. Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/ TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279:1615-22.
20. Elliott WJ, Weir DR. 1999. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am J Health Syst Pharm, 56:1726-32.
21. Ferrer-García JC, Pérez-Silvestre J, Martínez-Mir I, et al. 2006. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia. Acta Diabetol, 43:75-8.
22. Fonarow GC, French WJ, Parsons LS, et al. 2001. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3. Circulation, 103:38-44.
23. Ford ES, Giles WH, Mokdad AH. 2004. Increasing prevalence of the metabolic syndrome among US Adults. Diabetes Care, 27:2444-9.
24. Frost PH, Davis BR, Burlando AJ, et al. for the Systolic Hypertension in the Elderly Research Group. 1996. Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP). Circulation, 94:2381-8.
25. Ghosh S, Ziesmer V, Aronow WS. 2002. Underutilization of aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and lipid-lowering drugs and overutilization of calcium channel blockers in older persons with coronary artery disease in an academic nursing home. J Gerontol A Biol Sci Med Sci, 57:M398-400.
26. Grundy SM, Cleeman JI, Bairey Merz CN, et al. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation, 110:227-39.
27. Houterman S, Verschuren WM, Hofman A, et al. 1999. Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study. J Intern Med, 246:25-33.
28. [HPSCG] Heart Protection Study Collaborative Group. 2002. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 360:7-22.
29. Hunt D, Young P, Simes J, et al. 2001. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med, 134:931-40.
30. Huse DM, Russell MW, Miller JD, et al. 1998. Cost-effectiveness of statins. Am J Cardiol, 82:1357-63.
31. Jackevicius CA, Mamdani M, Tu JV. 2002, Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA, 288:462-7.
32. Jafari M, Ebrahimi R, Ahmadi-Kashani M, et al. 2003. Efficacy of alternate-day dosing versus daily dosing of atorvastatin. J Cardiovasc Pharmacol Ther, 8:123-6.
33. Jialal I, Stein D, Balis D, et al. 2001. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation, 103:1933-5.
34. Juszczyk MA, Seip RL, Thompson PD. 2005. Decreasing LDL cholesterol and medication cost with every-other-day statin therapy. Prev Cardiol, 8:197-9.
35. Kronmal RA, Cain KC, Ye Z, et al. 1993. Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data. Arch Intern med, 153:1065-73.
36. LaRosa JC, Grundy SM, Waters DD, et al.; Treating to New Targets (TNT) Investigators. 2005. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 352:1425-35.
37. Laufs U, Wassmann S, Hilgers S, et al. 2001. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, noncholesterolemic men. Am J Cardiol, 88:1306-7.
38. Law M, Rudnicka AR. 2006. Statin safety: a systematic review. Am J Cardiol, 97:52C-60C.
39. Lea AP, McTavish D. 1997. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidemias. Drugs, 53:828-47.
40. Lewis SJ, Moye LA, Sacks FM, et al. for the CARE Investigators. 1998. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Ann Intern Med, 129:681-9.
41. LIPID Study Group. 1998. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. 1998. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 339:1349-57.
42. Lloyd-Jones DM, Larson MG, Beiser A, et al. 1999. Lifetime fisk of developing coronary heart disease. Lancet, 353:89-92.
43. Marchesi S, Lupattelli G, Siepi D, et al. 2000. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol, 36:617-21.
44. Martinez-Gonzalez J, Badimon L. 2007. Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des, 13:1771-86.
45. Matalka MS, Ravnan MC, Deedwania PC. 2002. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J, 144:674-7.
46. McCarey DW, McInnes IB, Madhok R, et al. 2004. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet, 363:2015-21.
47. Miettinen TA, Pyorala K, Olsson AG, et al. for the Scandinavian Simvastatin Study Group. 1997. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: Findings from the Scandinavian Simvastatin Survival Study (4S). Circulation, 96:4211-8.
48. Miller PS, Smith DG, Jones P. 2005. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). Am J Cardiol, 95:1314-9.
49. Minitino AM, Heron MP, Murphy SL, et al. 2007. Deaths: Final Data for 2004. Natl Vital Stat Rep, 55:1-119.
50. Muldoon ME, Barger SD, Ryan CM, et al. 2000. Effects of lovastatin on cognitive function and psychological well-being. Am J Med, 108:538-46.
51. Muldoon MF, Ryan CM, Sereika SM, et al. 2004. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med, 117:823-9.
52. NCEP 2001. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285:2486-97.
53. Neil HA, DeMicco DA, Luo D, et al.; CARDS Study Investigators. 2006. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care, 11:2378-84.
54. Nissen SE, Tuzcu EM, Schoenhagen P, et al. 2004. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 291:1071-80.
55. Nissen SE, Tuzcu EM, Schoenhagen P, et al. 2005. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med, 352:29-38.
56. Olsson AG, Schwartz GG, Szarek M, et al. 2007. Effects of high-dose atorvastatin in patients ≥65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am J Cardiol, 99:632-5.
57. Pedersen TR, Kjekshus J, Berg K, et al; Scandinavian Siravastatin Survival Study Group. 1994. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344:1383-9.
58. Pedersen TR, Faergeman O, Kastelein JJP, et al. 2005. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA, 294:2437-45.
59. Piamsomboon C, Laothavorn P, Saguanwong S, et al. 2002. Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia. J Med Assoc Thai, 85:297-300.
60. Prueksaritanont T, Zhao JJ, Ma B, et al. 2002. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther, 301:1042-51.
61. Rasmussen JN, Gislason GH, Abilstrom SZ, et al. 2005. Statin use after acute myocardial infarction: a nationwide study in Denmark. Br J Pharmacol, 60:150-8.
62. Ray KK, Bach RG, Cannon CP, et al.; PROVE IT-TIMI 22 Investigators. 2006. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS. Eur Heart J, 27:2310-6.
63. Roberts CG, Guallar E, Rodriguez A. 2007. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci, 62:879-87.
64. Rosamond W, Flegal K, Friday G, et al. 2007. Heart disease and stroke statistics - 2007 update. A report from the American Heart Association statistics committee and stroke statistics subcommittee. Circulation, 115:e69-172.
65. Rubin SM, Sidney S, Black DM, et al. 1990. High blood cholesterol in elderly men and the excess risk for coronary heart disease. Ann Intern Med, 113:916-20.
66. Sacks FM, Pfeffer MA, Moye LA, et al. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. (Cholesterol and Recurrent Events Investigators). N Engl J Med, 335:1001-9.
67. Schartl M, Bocksch W, Koschyk DH, et al. 2001. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation, 104:387-92.
68. Schwartz GG, Olsson AG, Ezekowitz MD, et al.; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. 2001. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 285:1711-8.
69. Seljeflot I, Tonstad S, Hjermann I, et al. 2002. Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis, 162:179-85.
70. Sever, PS, Dahlof B, Poulter NR, et al. 2003. Prevention of coronary and stroke vents with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multi-centre randomised controlled trial. Lancet, 361:1149-58.
71. Shepherd J, Cobbe SM, Ford I, et al. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group (WOSCOPS). N Engl J Med, 333:1301-7.
72. Shepherd J, Blauw GJ, Murphy MB, et al. 2002. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 360:1623-30.
73. Shipley MJ, Pocock SJ, Marmot MG. 1991. Does plasma cholesterol concentration predict mortality from coronary heart disease in elderly people? 18 year follow up in the Whitehall Study. BMJ, 303:89-92.
74. Smith JC Jr, Allen J, Blair SN, et al. 2006. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung and Blood Institute. Circulation, 113:2363-72.
75. Szapary L, Horvath B, Marton Z, et al. 2004. Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidemia. CNS Drugs, 18:165-72.
76. Thompson GR, Naoumova RP, and Watts GF. 1996. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res, 37:439-47.
77. Tonkin AM, Eckermann S, White H, et al. 2006. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study. Am Heart J, 151:1305-12.
78. [UN] Population Division, DESA, United Nations. 2001. World Population Ageing 1950-2050, [online]. Accessed 27 Sept 2007. URL: http://www.un.org/esa/population/publications/worldageing19502050.
79. van Wissen S, Trip MD, Smilde TJ, et al. 2002. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis, 165: 361-66.
80. Ward S, Lloyd Jones M, Pandor A, et al. 2007. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess, 11:1-160, iii-iv.
81. Wenger NK, Lewis SJ, Herrington DM, et al.; Treating to New Targets Study Steering Committee and Investigators. 2007. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med, 147:1-9.
82. Zhou S, Chan SY, Goh BC, et al. 2005. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet, 44:279-304.